Clinical trials: Concentration
Attention Deficit Hyperactivity Disorder (ADHD)
Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary study objective is to evaluate the efficacy of Vayarin in ADHD adults.
- Trial name
- NCT02257216
- Testing
- Vayarin®
- Where
- 4 sites in United States
- Volunteers
- 171 people
- Sponsor
- Enzymotec
Healthy Volunteers, Pharmacokinetics of Mirabegron
A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously
This study investigates whether mirabegron (YM178) has an effect on the pharmacokinetics of solifenacin and whether solifenacin has an effect on the pharmacokinetics of mirabegron.
- Trial name
- NCT01297192
- Testing
- solifenacin succinate, mirabegron
- Where
- France
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
- Trial name
- BE CARING (NCT06888193)
- Testing
- Bimekizumab
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 20 people
- Sponsor
- UCB Biopharma SRL
Dry Eye Disease
Safety Study of Lifitegrast to Treat Dry Eye
The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1…
- Trial name
- SONATA (NCT01636206)
- Testing
- Lifitegrast
- Where
- 23 sites in United States
- Volunteers
- 332 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1).
- Trial name
- NCT00191945
- Testing
- Atomoxetine Hydrochloride
- Where
- 11 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Chronic Kidney Disease, End-Stage Renal Disease
Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis
This trial is conducted in Europe. The aim of this trial is to to compare steady-state total growth hormone (GH) exposure in haemodialysis (HD) patients with that of matched healthy subjects.
- Conditions
- Chronic Kidney Disease, End-Stage Renal Disease, Healthy
- Trial name
- NCT01502137
- Testing
- somatropin
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Attention Deficit Hyperactivity Disorder
Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
The objective is to assess overall safety and tolerability of atomoxetine in doses up to 120 mg/day in Japanese adult patients who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for…
- Trial name
- NCT00530335
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult…
- Trial name
- NCT00636818
- Testing
- Atomoxetine
- Where
- 11 sites in China, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
ADHD - Combined Type, ADHD
Ocular-vestibular Biomarker Identification for ADHD
This study intends to establish a relationship between oculovestibular eye tracking measures, measures of ADHD, and medication prescribed for ADHD.
- Conditions
- ADHD - Combined Type, ADHD, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
- Trial name
- NCT04504890
- Testing
- EYE-SYNC
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Sync-Think, Inc.
Healthy Subjects
Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)
The primary objective of this study is to measure and compare the concentration of AAI101 and cefepime in bronchial epithelial lining fluid (ELF) and plasma following administration of cefepime/AAI101 combination in healthy…
- Trial name
- NCT03680378
- Testing
- Cefepime 2 gram
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Allecra
Attention Deficit/Hyperactivity Disorder
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P01 (NCT05685732)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 246 people
- Sponsor
- Corium, Inc.
Anemia
Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.
This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin.
- Trial name
- NCT00223938
- Testing
- Oral Iron, sodium ferric gluconate
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- Sanofi
Sweat Analysis
NBA G-League Sweat Testing Study: Validity of the Gx Sweat Patch in Measuring Sweating Rate and Sweat Chloride Concentration During On-court Training With Basketball Players
To determine the validity of the Gx Sweat Patch in measuring sweating rate and sweat chloride concentration during moderate-high intensity practice against well-established reference methods in field conditions with basketball…
- Trial name
- NCT04679532
- Testing
- Gx sweat patch, Reference sweat patch
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Cough
A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female…
- Trial name
- NCT06497517
- Testing
- GSK5464714- Camlipixant
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bellus Health Inc. - a GSK company
Psoriasis
Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test
The aim of the exploratory study is to compare dose related effects of LAS41004 formulations in a non-occlusive PPT.
- Trial name
- PPT4 (NCT01462643)
- Testing
- LAS41004
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Almirall, S.A.
ADHD
AR08 for Treatment of ADHD in Children
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio.
- Trial name
- NCT01876719
- Testing
- AR08
- Where
- 13 sites in United States
- Volunteers
- 122 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Therapeutic Gaming for the Treatment of Attention Deficit Hyperactivity Disorder
Children with ADHD play a videogame to test symptom control
- Trial name
- THERAGAME (NCT05067322)
- Testing
- Minecraft
- Volunteers
- 2 people
- Sponsor
- Spherix Incorporated
Attention Deficit Disorder With Hyperactivity
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
The overall primary objective of this study is to test the hypothesis that, compared with placebo,administration of atomoxetine will result in an improved work productivity.
- Trial name
- NCT00190931
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
SARS-CoV-2 Infection
Study of a Live rNDV Based Vaccine Against COVID-19
This is a Phase 1, open-label, non-randomized, dose-escalation study using three doses and two schemes of administration of a recombinant vaccine against SARS-CoV-2 based on a viral vector (Newcastle Disease virus) in 90 healthy…
- Trial name
- NCT04871737
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- Mexico
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.